List of drugs that have PK results

All PK reports can be found in the CSTN Data Portal.

Abemaciclib
Abemaciclib (inter-group qualification)
Alisertib
AZD-1390
Adavosertib(AZD-1775)
AZD-6738
Binimetinib
Bortezomib
Buparlisib
Cabozantinib
Carfilzomib
Ceritinib
CX-5461
Dactolisib
DactolisibPK (project summary)
Ensartinib

Erdafitinib
Fostamatinib
(Fos)tamatinib (Ocular)
Ganetespib
Gedatolisib
Idasanutlin
Irinotecan & SN38 (ES-8)
Irinotecan & SN38 (O-PDX)
Liposomal irinotecan (Onivyde)
Larotrectinib
Linsitinib
LY3023414
Olaparib
Palbociclib
Panobinostat
Panobinostat (Lactic Acid)

Panobinostat (Ocular)
Pazopanib
Selinexor
Selumetinib
Sorafenib
Talazoparib
Taselisib
Tazemetostat (plasma)
Tazemetostat (O-PDX single dose)
Tazemetostat: (O-PDX multiple dose)
Trametinib
Ulixertinib
Veliparib
VX-970


List of drugs included in HTS screening

5-Fluorodeoxycytidine
5-Fluorouracil (5-FU)
6-Mercaptopurine
6-Thioguanine
7-Hydroxystaurosporine
Abiraterone Acetate
Actinomycin D
Afatinib
Alisertib
Arimidex
Arry-520
Artesunate
Aurorafin
Axinitib
Azacitidine
AZD-1775
AZD-4547
AZD-5363
AZD-7762
Binimetinib
Blenoxane
Bmn673 (Talazoparib)
Bms-777607
Bordoxolone
Bortezomib
Bosisunib
Brivudine
Buparlisib
Cabazitaxel
Cabozantinib
Carfilzomib
Ceritinib
Chlorambucil
Ciclopirox
Cladribine
Clofarabine
Cobimetinib
Crenolanib
Crizotinib
Cyclophosphamide
Cyt11387
Cytadren
Cytidine
Dabrafenib
Daclctisib
Dacogen
Daraprim
Dasatinib
Dexamthasone
Dfmo
Dihydroartemisinin (DHA)
Docetaxol
Doxorubicin

ENMD-981693
Enzalutamide
Erlotinib
Etoposide
Everolimus
Fedratinib
Floxuridine
Fludara
Fluphenazine HCL
Fluvastatin
Foretinib
Ganetespib
GDC-0068
GDC-0199
GDC-0994
Gedatolisib
Gefifinib
Gemcitabine
GMX-1778
Golotimod
Hydroxychloroquine
Idronoxil
Ifosfamide
Itraconazole
Ixabepilone
JQ1
Lapatinib
LEE011
Leflunomide
LGX-818
LY2157299
Masitinib
Mepacrine
Methotrexate
Midostaurin
Mithramycin
Mitomycin
Mitotane
Mitoxantrone
MK-2206
MK-8776
Motatenib Diphosphate
Mycophenolate Mofetil Hydrochloride
Namenda
Navitoclax
Neratinib
Niftfuimox
Nililonib
Nimtmuine
Noscapine
NSC-617593
NSC-714598 | NSC-286644
Obatoclax

Olaparib
Omipalisib
Ouabain
Pacritnib
Palbociclib
Panobinostat
Pazopanib
PD 325901
Pemetrexed Disodium
Pentostatin
Pimasertib
Pioglitazone
Ponatinib
Rabusertib
Raltitrexed
Regorafenib
Retinoic Acid
RG7112
Romidepsin
Ruxolitinib
Selinexor
Selumetinib
Sirolimus
SN-38
Sorafenib
Streptozotocin
Sulindac
Sunitinib
Tamibarotene
Tamoxifen
Targretin Bexarotene
Taselisib
Tazarotene
Temozolomide
Temsirolimus
Tivantinib
Tivozanib
Topotecan
Trametinib
Trimetrexate
Trisenox
Vantndanib
VE821
Vemurafenib
Vinblastine
Vincristine
Vinorelbine
Vismodegib
Volelartib
Vorinostat
Vosaroxin


Preclinical Phase 1

Vincristine + Irinotecan (Low-dose protracted)
Vincristine + Irinotecan (High-dose 5 day dosing)
Vincristine + Irinotecan + Panobinostat
Vinorelbine + Cyclophosphamide
Panobinostat + Bortezomib
Vincristine + Dactinomycin + Cyclophosphamide
Cisplatin + Doxorubicin + Methotrexate + Ifosfamide + Etoposide (MAP/IE)
Gemcitabine + Docetaxel
Cyclophosphamide + Doxorubicin + Etoposide
Cisplatin + Etoposide
Irinotecan + Temozolomide
BMN-673 + Irinotecan + Temozolomide
Olaparib + Irinotecan + Temozolomide
Veliparib + Irinotecan + Temozolomide


Preclinical Phase II

SHRHB026_X1:  Vincristine + Irinotecan
SHRHB026_X1:  Panobinostat
SHRHB026_X1:  Panobinostat + Bortezomib
SHRHB026_X1:  Vincristine + Dactinomycin + Cyclophosphamide

SHRHB026_X2:  Vincristine + Dactinomycin + Cyclophosphamide
SHRHB026_X2:  Vinorelbine + Cyclophosphamide

SJRHB010927_X1:  Vincristine + Dactinomycin + Cyclophosphamide

SJRHB012_Y:  Vincristine + Irinotecan
SJRHB012_Y:  Panobinostat + Bortezomib

SJRHB013759_X1:  Vincristine + Irinotecan
SJRHB013759_X1:  Panobinostat + Bortezomib

Neuroblastoma

SJNBL046_X:  Cyclophosphamide + Doxorubicin + Etoposide / Cisplatin + Etoposide
SJNBL046_X:  OSI-906 + BEZ-235
SJNBL046_X:  OSI-906 + BKM-120

NB5:  Cyclophosphamide + Doxorubicin + Etoposide / Cisplatin + Etoposide
NB5:  OSI-906 + BEZ-235
NB5:  OSI-906 + BKM-120

Ewing sarcoma

ES-8: Irinotecan + Temozolomide
ES-8: BMN-673 + Irinotecan + Temozolomide
ES-8: Olaparib + Irinotecan + Temozolomide
ES-8: Veliparib + Irinotecan + Temozolomide
EW-8: Irinotecan + Temozolomide
EW-8: BMN-673 + Irinotecan + Temozolomide
EW-8: Olaparib + Irinotecan + Temozolomide
EW-8: Veliparib + Irinotecan + Temozolomide
ES-6: Irinotecan + Temozolomide
ES-6: BMN-673 + Irinotecan + Temozolomide
ES-6: Olaparib + Irinotecan + Temozolomide
ES-2: Irinotecan + Temozolomide
ES-2: BMN-673 + Irinotecan + Temozolomide
ES-3: Irinotecan + Temozolomide
ES-3: BMN-673 + Irinotecan + Temozolomide


Preclinical Phase III

Ewing Sarcoma

ES-8:  PARP inhibitor trial (BMN-673, Olaparib, Veliparib, Irinotecan, Temozolamide)